ArticleScience translational medicine2019
Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors.
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Molecular and therapeutic frontiers in anemia therapy.The Journal of clinical investigation · 2026Review
- Synthesis of tetrahydroisoquinoline-fused polycyclic heterocyclic skeletons via Vilsmeier-reagent promoted decarbonylative annulation.Communications chemistry · 2026Article
- Advances and challenges in the treatment of myelodysplastic syndromes.Experimental hematology & oncology · 2025Review
- Role of Neurotransmitters in Steady State Hematopoiesis, Aging, and Leukemia.Stem cell reviews and reports · 2025Review
- Contemporary insights into neuroimmune interactions across development and aging.Frontiers in neurology · 2025Review
- Anticholinergic burden and clinical outcomes among older adults admitted in a tertiary hospital: a prospective cohort study.PloS one · 2025Article
- BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state.Nature communications · 2023Article
- Macrophages Provide Essential Support for Erythropoiesis, and Extracellular ATP Contributes to a Erythropoiesis-Supportive Microenvironment during Repeated Psychological Stress.International journal of molecular sciences · 2023Article
- Vagal-mAChR4 signaling promotes Friend virus complex (FV)-induced acute erythroleukemia.Virologica Sinica · 2023Article
- CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.Cell death & disease · 2023Article
- FACS and immunomagnetic isolation of early erythroid progenitor cells from mouse fetal liver.STAR protocols · 2022Article
- Targeting Stress Erythropoiesis Pathways in Cancer.Frontiers in physiology · 2022Review
- The Interplay between Anticholinergic Burden and Anemia in Relation to 1-Year Mortality among Older Patients Discharged from Acute Care Hospitals.Journal of clinical medicine · 2021Article
- Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies.Trends in molecular medicine · 2021Review
- Neuronal regulation of bone marrow stem cell niches.F1000Research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Adult stem and progenitor cells are uniquely capable of self-renewal, and targeting this process represents a potential therapeutic opportunity. The early erythroid progenitor, burst-forming unit erythroid (BFU-E), has substantial self-renewal potential and serves as a key cell type for the treatment of anemias. However, our understanding of mechanisms underlying BFU-E self-renewal is extremely limited. Here, we found that the muscarinic acetylcholine receptor, cholinergic receptor, muscarinic 4 (CHRM4), pathway regulates BFU-E self-renewal and that pharmacological inhibition of CHRM4 corrects anemias of myelodysplastic syndrome (MDS), aging, and hemolysis. Genetic down-regulation of CHRM4 or pharmacologic inhibition of CHRM4 using the selective antagonist PD102807 promoted BFU-E self-renewal, whereas deletion of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.